ReCode Therapeutics, Inc. Overview
Pro stress-test →ReCode Therapeutics is a clinical-stage genetic medicines company powering the future of genetic medicines with precision delivery. The company's selective organ targeting (SORT) lipid nanoparticle (LNP) platform enables precise delivery to target organs and cells beyond the liver.
Strategic Profile
Pro stress-test →ReCode develops targeted, disease-modifying medicines for patients with life-limiting respiratory diseases. The company's lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode has raised a total of $260 million in funding through its Series B extension (September 2023).
Competitive Landscape
Pro stress-test →ReCode competes in the genetic medicines and RNA therapeutics space against broader platforms like Moderna and BioNTech, though these players focus more broadly. In rare respiratory genetic medicines, ReCode faces competition from gene therapy companies like Vertex Pharmaceuticals (which offers CFTR modulators) and emerging precision delivery competitors. ReCode's differentiation lies in its tissue-specific organ targeting capability beyond hepatic delivery, addressing Class I CF mutations and primary ciliary dyskinesia where current standards of care are limited.
Industry Context
ReCode Therapeutics, Inc. operates in Genetic medicines with precision delivery.
Key facts
Founded: 2015 · Headquarters: Menlo Park, California & Dallas, Texas · Employees: 11-50 · Revenue: N/A · Market cap: N/A